Based on receiving China’s State Food and Drug Administration approval, Lepu will market the system in China under the name LEPU Quant-Gold.
Qiagen global strategic alliances and OEM head Frank Krieg-Schneider said the company is meeting a pressing need for heart patients by combining ESEQuant’s quick turnaround time with the reliability of Lepu’s tests for cardiac biomarkers.
"This agreement advances two strategic initiatives: First, our geographic presence is further broadened by the addition of important point of need assays in China," Krieg-Schneider added.
"Secondly, we are driving platform success by launching ESEQuant as an SFDA-approved device in a lifesaving medical application, a milestone for our emerging Point of Need portfolio."
